Macrophage's Promotion of Cervical Cancer Cell Resistance to SN-38

LAI Lili; JIN Huan; DUAN Huaying; ZOU Zhengzhi

doi:10.6054/j.jscnun.2021010

Journal of South China Normal University (Natural Science Edition) > 2021 > 53(1): 63-69. > DOI: 10.6054/j.jscnun.2021010

LAI Lili, JIN Huan, DUAN Huaying, ZOU Zhengzhi. Macrophage's Promotion of Cervical Cancer Cell Resistance to SN-38[J]. Journal of South China Normal University (Natural Science Edition), 2021, 53(1): 63-69. DOI: 10.6054/j.jscnun.2021010

Citation:

PDF (1130 KB)

Macrophage's Promotion of Cervical Cancer Cell Resistance to SN-38

1.
Department of Obstetrics and Gynecology, Zengcheng District People's Hospital, Guangzhou 511300, China
2.
MOE Key Laboratory of Laser Life Science and Institute of Laser Life Science, College of Biophotonics, South China Normal University, Guangzhou 510631, China
3.
Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China

More Information

Received Date: April 06, 2020
Available Online: March 23, 2021

Graphical Abstract

Abstract

Abstract

GDSC (Genomics of Drug Sensitivity in Cancer) online database was analyzed and the IC₅₀ Z Score values of 8 cervical cancer cell lines under more than 310 chemotherapy drugs were obtained. Then HPV-18 positive HeLa cells, HPV-16 positive SiHa and CaSki cells and HPV negative C-33A cells were treated with SN-38 for 24 and 48 hours and the cell viability was detected with CCK8 experiment. Finally, THP1 cells were induced into tumor-associated macrophages (TAM) to explore the role of TAM in the sensitivity of cervical cancer cells to SN-38. The results showed that CaSki, ME-180, HT-3 and C-33A were very sensitive to SN-38, HeLa and SiHa were relatively sensitive to SN-38, and CAL-39 was not sensitive to SN-38. In addition, IC₅₀ values of CaSki and C-33A were lower than those of HeLa and SiHa, indicating that CaSki and C-33A were more sensitive to SN-38. TAM promoted HeLa and SiHa cell resistance to SN-38. In conclusion, the results suggested that TAM promoted the resistance of cervical cancer cells to SN-38.
- macrophages,
- cervical cancer,
- SN-38

FullText(HTML)

References (27)

References

[1]	ARBYN M, WEIDERPASS E, BRUNI L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis[J]. The Lancet Global Health, 2019, 8(2): 191-203. http://www.sciencedirect.com/science/article/pii/S2214109X19304826
[2]	COHEN P, JHINGRAN A, OAKNIN A, et al. Cervical cancer[J]. The Lance, 2019, 393(10167): 169-182. doi: 10.1016/S0140-6736(18)32470-X
[3]	SARFATI D, DYER R, SAM L, et al. Cancer control in the Pacific: big challenges facing small island states[J]. The Lancet Oncology, 2019, 20(9): 475-492. doi: 10.1016/S1470-2045(19)30400-0
[4]	KAWATO Y, AONUMA M, HIROTA Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11[J]. Cancer Research, 1991, 51(16): 4187-4191. http://chromsci.oxfordjournals.org/cgi/ijlink?linkType=ABST&journalCode=canres&resid=51/16/4187
[5]	SUN X F, FERREUD L, SVANVIK J, et al. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential[J]. Oncology Reports, 2008, 19(6): 1493-1498. http://europepmc.org/abstract/med/18497955
[6]	FRANK A, AGAMA K, ROY A, et al. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations[J]. Journal of Experimental & Clinical Cancer Research, 2016, 35(1): 56-69. http://europepmc.org/articles/PMC4815242/
[7]	CHEN P, LUO X, NIE P, et al. CQ synergistically sensitizes human colorectal cancer cells to SN-38/CPT-11 through lysosomal and mitochondrial apoptotic pathway via p53-ROS cross-talk[J]. Free Radical Biology and Medicine, 2017, 104: 280-297. doi: 10.1016/j.freeradbiomed.2017.01.033
[8]	CARDILLO T M, GOVINDAN S V, SHARKEY R M, et al. Sacituzumab govitecan (IMMU-132), an anti-trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers[J]. Bioconjugate Chemistry, 2015, 26(5): 919-931. doi: 10.1021/acs.bioconjchem.5b00223
[9]	BARDIA A, MAYER I A, VAHDAT L T, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer[J]. New England Journal of Medicine, 2019, 380(8): 741-751. doi: 10.1056/NEJMoa1814213
[10]	GOLDENBERG D M, SHARKEY R M. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan[J]. Taylor & Francis, 2019, 11(6): 987-995. doi: 10.1080/19420862.2019.1632115
[11]	LIU Y, XING H, WENG D, et al. Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer[J]. Cancer Letters, 2009, 274(1): 47-53. doi: 10.1016/j.canlet.2008.08.037
[12]	OHARA T, KOBAYASHI Y, YOSHIDA A, et al. Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer[J]. International Journal of Clinical Oncology, 2012, 18(6): 1102-1106. http://europepmc.org/abstract/MED/23095879
[13]	SHOJI T, TAKATORI E, FURUTAKE Y, et al. Phase Ⅱ clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky mass[J]. International Journal of Clinical Oncology, 2016, 21(6): 1120-1127. doi: 10.1007/s10147-016-1008-7
[14]	CHEN Y B, SONG Y C, DU W, et al. Tumor-associated macrophages: an accomplice in solid tumor progression[J]. Journal of Biomedical Science, 2019, 26(1): 1-13. doi: 10.1186/s12929-018-0495-4
[15]	HU H, TU W, CHEN Y, et al. The combination of PKM2 overexpression and M2 macrophages infiltration confers a poor prognosis for PDAC patients[J]. Journal of Cancer, 2020, 11(8): 2022-2031. doi: 10.7150/jca.38981
[16]	JIN J Y, WANG Y, MA Q L, et al. LAIR-1 activation inhibits inflammatory macrophage phenotype in vitro[J]. Cellular Immunology, 2018, 331(1): 78-84. http://www.sciencedirect.com/science/article/pii/S0008874918302508
[17]	邹争志, 聂培培, 倪艺榕, 等. 硫链丝菌素诱导非小细胞肺癌细胞自噬性死亡[J]. 激光生物学报, 2014, 23(1): 33-37. doi: 10.3969/j.issn.1007-7146.2014.01.006 ZOU Z Z, NIE P P, NI Y R, et al. Thiostrepton induces autophagic cell death in non-small-cell lung cancer cells[J]. Acta Laser Biology Sinica, 2014, 23(1): 33-37. doi: 10.3969/j.issn.1007-7146.2014.01.006
[18]	YANG W, SOARES J, GRENINGER P, et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells[J]. Nucleic Acids Research, 2013, 41(1): 955-961. http://www.tandfonline.com/servlet/linkout?suffix=CIT0012&dbid=8&doi=10.1080%2F17460441.2018.1437136&key=23180760
[19]	彭程, 薛海军, 常晓晓, 等. 不同品种黄皮果汁的品质及抗氧化能力[J]. 华南师范大学学报(自然科学版), 2020, 52(1): 70-76. doi: 10.6054/j.jscnun.2020011 PENG C, XUE H J, CHANG X X, et al. The quality and antioxidant capacity of fruit Juice of different wampee cultivars[J]. Journal of South China Normal University (Natural Science Edition), 2020, 52(1): 70-76. doi: 10.6054/j.jscnun.2020011
[20]	QIAO J H, CHEN Y B, MI Y J, et al. Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE[J]. Biochemical Pharmacology, 2020, 10(180): 114-126. http://www.sciencedirect.com/science/article/pii/S0006295220303622
[21]	PATHRIA P, JUDITH A, VARNER J A, et al. Targeting tumor-associated macrophages in cancer[J]. Trends in Immunology, 2019, 40(4): 310-327. doi: 10.1016/j.it.2019.02.003
[22]	WANG Q, STEGER A, MAHNER S, et al. The formation and therapeutic update of tumor-associated macrophages in cervical cancer[J]. International Journal of Molecular Sciences, 2019, 20(13): 1059-1069.
[23]	BAHRAMI A, HASANZADEH M, HASSANIAN S M, et al. The potential value of the PI3K/Akt/mTOR signaling pathway for assessing prognosis in cervical cancer and as a target for therapy[J]. Journal of Cellular Biochemistry, 2017, 118(12): 4163-4169. doi: 10.1002/jcb.26118
[24]	DAI B, YU R, FAN M, et al. HMQ-T-F2 suppresses migration of the human cervical cancer HeLa cells by reversing EMT via the PI3K/Akt signaling pathway[J]. Oncology Reports, 2019, 42(4): 1451-1458. http://www.researchgate.net/publication/334637080_HMQ-T-F2_suppresses_migration_of_the_human_cervical_cancer_HeLa_cells_by_reversing_EMT_via_the_PI3KAkt_signaling_pathway
[25]	D'ERRICO G, ALONSO N M, MIREIA V, et al. Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance[J]. Oncogene, 2019, 38(27): 5469-5485. doi: 10.1038/s41388-019-0803-9
[26]	LI D, JI H, NIU X, et al. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer[J]. Cancer Science, 2020, 111(1): 47-58. doi: 10.1111/cas.14230
[27]	WEI C, YANG C, WANG S, et al. M2 macrophages confer resistance to 5-fluorouracil in colorectal cancer through the activation of CCL22/PI3K/AKT signaling[J]. OncoTargets and Therapy, 2019, 12(1): 3051-3063. http://www.researchgate.net/publication/332487487_M2_macrophages_confer_resistance_to_5-fluorouracil_in_colorectal_cancer_through_the_activation_of_CCL22PI3KAKT_signaling

Cited By

Get Citation

PDF

XML

Article views PDF downloads

Turn off MathJax

Article Contents

Abstract

References

Macrophage's Promotion of Cervical Cancer Cell Resistance to SN-38

Abstract

References

Catalog

Export File

Citation

Format

Content